Articles tagged with Vaccination
A mass dog vaccination program can stop agonizing rabies deaths worldwide by targeting the virus's primary source: dogs. By vaccinating 70% of dogs in high-risk areas, transmission from dogs to humans can be broken, leading to a significant decline in human cases.
Researchers found Streptococcus pneumoniae physically damages the heart, leaving tiny lesions that can permanently scar the myocardium. A candidate vaccine has been developed to protect against this damage.
Neglected tropical diseases (NTDs) affect 14-15% of cases in Bolivia, Ecuador, Nicaragua, and Venezuela, despite the countries' small population. The US could work with these countries to implement disease control programs and develop lifesaving vaccines through joint efforts.
Grand Challenges Canada announces $2.4 million in grants for 22 innovative projects addressing maternal, newborn and child health globally. These projects include programs improving infant nutrition, malaria diagnosis, and vaccine storage, as well as initiatives to combat iron deficiency and improve access to healthcare.
Researchers have identified a better measure of predicting cancer neoepitopes, which are specific protein sequences recognized by immune cells. This new approach has the potential to improve current methods for generating anticancer vaccines, increasing their effectiveness in combating cancer.
Researchers at LA BioMed are developing a vaccine to protect patients from healthcare-related infections such as Candida and MRSA. The NIH grant will support the study of samples from patients enrolled in an ongoing clinical trial to assess the efficacy of the vaccine.
A study found that measles illness lasts for almost 14 days and causes people to miss nearly 10 days at work or school on average. The analysis also showed that the average number of quality-adjusted life years (QALYs) lost due to measles is 0.019 per patient, equivalent to 6.9 QALYs.
Researchers have successfully tested a new vaccine regimen that provides rapid protection against Ebola virus in monkeys, with some animals remaining protected for up to 10 months after vaccination. The experimental ChAd3 Ebola vaccine demonstrated strong immune responses in both single-dose and prime-boost regimens.
A study from the University of Sydney reveals a 61% decrease in genital wart management among young women since the introduction of the free HPV vaccination program. The vaccine has been effective in reducing genital warts and their treatment costs, with no significant change in other sexually transmitted infections.
Researchers at Technical University of Munich have discovered a new site where T lymphocytes can be programmed to attack pathogens. The liver plays a key role in this process, and synthetic messenger Hyper-IL-6 has been found to efficiently activate T cells, offering a promising new adjuvant for vaccine formulations.
A new vaccine candidate, GP2, has shown a 57% reduction in recurrence rates among high-risk breast cancer patients. The vaccine targets CD8+ cells and was combined with an immune stimulant to enhance its effectiveness.
A blend of three monoclonal antibodies has been shown to protect monkeys against a lethal dose of Ebola virus for up to 5 days after infection. This treatment, ZMAPP, was found to be effective in a study published in Nature.
The National Institute of Allergy and Infectious Diseases (NIAID) has launched an initial human safety study for an Ebola vaccine candidate. The trial is the first in a series of Phase 1 clinical trials that will examine the investigational NIAID/GSK Ebola vaccine, which is designed to induce an immune response in healthy adults.
A CU Denver study reveals that vaccine refusal is more common among children from higher-income families with educated mothers. These parents often rely on alternative practices like breastfeeding and social monitoring to prevent disease, rather than vaccinations. In contrast, lower-income families face barriers to accessing healthcare...
The 2009 H1N1 outbreak at Washington State University provided valuable data for researchers to study the rapid spread of the virus. A computer model revealed that only a few initial infected individuals sparked the outbreak, with a high transmissibility rate among close-knit student communities.
A new report by Princeton University researchers suggests that expanding the age of eligibility for measles vaccination from 12 to 15 months could significantly increase coverage in Africa. The study found that increasing the age range would have the most impact on countries with high rates of unvaccinated children.
Two commentaries in Annals of Internal Medicine emphasize the need for immediate Ebola vaccine deployment and cautious approach to containment plans. The authors argue that safety risks from vaccines are negligible compared to healthcare worker risks, while excessive measures can foster mistrust and increase risk.
A new vaccine, rBCG30, offers superior protection against tuberculosis in animal models and cross-protection against leprosy. Boosting rBCG30 with the Antigen 85B protein significantly enhances its effectiveness against leprosy.
Two new vaccines have been shown to prevent the transmission of meningitis bacteria from person to person, reducing carriage rates by up to 39% and 20-30%. This discovery could provide a degree of herd protection against meningitis if implemented in a campaign.
Researchers found that personal biases and communication styles of providers played a significant role in decreasing HPV vaccination rates among teens. Providers who believed their patients were at low risk for sexual activity delayed vaccine administration, often without readdressing the decision.
A new virus-like particle vaccine has shown promising results in a human trial, generating antibodies that provide long-term protection against chikungunya. The vaccine, composed of non-infectious VLP particles, was well-tolerated and effective across different doses.
A new experimental chikungunya vaccine performed well in an early clinical trial, eliciting neutralizing antibodies in all participants and providing durable protection for at least 11 months. The vaccine, a virus-like particle (VLP) vaccine, was delivered without an adjuvant and prompted a robust immune response.
The HPV vaccine has resulted in a dramatic drop in genital warts among young Australians, with a 90% decrease in girls aged 12-17 and a 73% decrease in women between 18-26. The vaccine also showed an indirect protective effect among young men, leading to a 38% drop in genital warts.
The BCG vaccine has a 60-80% protective efficacy against severe forms of tuberculosis in children. Research found that the vaccine is effective against TB infection, with a 19% effectiveness rate among vaccinated children after exposure.
A Kaiser Permanente study found that older adults vaccinated against shingles are 42% less likely to develop the disease after undergoing chemotherapy. The vaccine also prevented hospitalizations for shingles among vaccinated patients, highlighting its importance in preventing long-term complications.
The study found that the HPV vaccine Cervarix provided 100% protection against HPV-16/18 infections over a period of 9.4 years, with high and sustained levels of IgG antibodies observed. The results suggest that the vaccine offered excellent persistence of protective immunity.
A new C. difficile vaccine has been shown to be 100 percent effective in protecting animal models from the deadly intestinal disease caused by Clostridium difficile. The vaccine protects against bacterial toxins and could prevent deadly complications such as severe diarrhea and bowel perforation.
A dedicated website for the MMR vaccine is proposed as a simple yet effective way to boost vaccination rates. The study found that providing parents with online information reduces concerns and is more cost-effective than traditional methods like leaflets or face-to-face consultations.
A website providing information on the measles, mumps and rubella (MMR) vaccine is the most cost-effective way to increase its uptake, with a potential saving of £9.20 per vaccination for the NHS. This method is also more convenient for parents seeking additional information about the vaccine.
A study found that minority women who received HPV vaccination even after becoming sexually active had lower rates of abnormal Pap test results. The study suggests that incomplete HPV vaccination may still offer some protection against cervical cancer and its precursors.
A new vaccine developed by researchers at the University of Iowa reduces lung inflammation caused by dust-mite allergens in both lab and animal tests. The vaccine uses a booster called CpG to alter the body's immune response, producing antibodies that dampen the damaging effects of dust-mites.
Researchers from NYU Langone will present new findings on tau immunotherapy and its potential for treating Alzheimer's disease. The presentations focus on the role of mitochondria and death receptors in amyloid toxicity, which may lead to improved treatment options for patients.
A novel AD vaccine, Plp-Adeno-X-CMV-(Aβ3-10)10-CpG, was administered via nasal mucosal inhalation to AD transgenic mouse models, producing strong T helper 2 humoral immune responses and reducing Aβ1-42-induced cytotoxicity. This approach offers a promising therapeutic strategy for Alzheimer's disease.
A recent study of over 500,000 Danish women found no increased risk of venous thromboembolism following quadrivalent HPV vaccination. The research, published in JAMA, used data from national registers to evaluate the potential link between the vaccine and blood clots.
A survey of 1,000 incoming Grand Valley State University students found that moral or religious beliefs were the primary obstacle to receiving the Human Papillomavirus (HPV) vaccine. The study, led by graduate physician assistant researchers, aimed to understand the influence of media on HPV and vaccine compliance.
Endemic infectious diseases continue to affect millions of individuals in the US, with racial and ethnic minorities disproportionately affected. Emerging vector-borne and zoonotic disease infections are threatening new areas and populations.
Scientists expect progress in developing an effective TB vaccine, with Phase IIa clinical trials underway. The new vaccine aims to activate both killer and helper cells for improved immune response.
A study found that a fifth of UK school age children visiting their doctor with a persistent cough could have whooping cough, even if they have been fully vaccinated. The research suggests that an adolescent booster vaccination is needed to protect against pertussis infection.
Researchers developed a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, reprogramming these intractable cancers. The vaccine, GVAX, consists of irradiated tumor cells modified to recruit immune cells, and boosted activity of molecular mechanisms that inhibit cancer-fighting immune cells.
Pertussis cases are rising globally, with an estimated 50 million cases and 300,000 deaths worldwide. Nurses can educate patients and the public on the importance of follow-up booster vaccinations to maintain immunity. Partnerships between healthcare organizations, schools, and communities can also help increase vaccination rates.
A recent study has identified a molecular pathway that could lead to a safer and more effective strep vaccine. The research discovered the genes responsible for producing a molecule that defines Group A Streptococcus, which causes over 700 million infections worldwide each year.
The combined MMRV vaccine has been associated with slightly higher rates of febrile seizures in young children, but these seizures are typically self-limiting and rarely have long-term effects. Researchers found a slight increase in the relative risk of febrile seizure with the MMRV vaccine compared to the separate MMR+V vaccine.
Researchers are developing a new, freeze-stable tetanus vaccine using lipid nanoparticles and a hollow microneedle system. The delivery device can target specific areas of the skin, increasing vaccine efficacy.
The University of Louisville has received a three-year, $5.5 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to develop new treatments and vaccines for various forms of cancer. Researchers will focus on plant-based pharmaceuticals and vaccines for cervical and colon cancer.
A Pittsburgh Supercomputing Center and Johns Hopkins Bloomberg School of Public Health team used HERMES modeling software to help the Republic of Benin redesign its vaccine delivery system, saving an estimated $500,000 in costs while improving vaccination rates.
A recent study found that rates of infant immunization with pertussis-containing vaccine did not increase during a pertussis epidemic in Washington state. Despite high risk, vaccination rates remained stable before and during the epidemic, suggesting that conventional wisdom about vaccine acceptance may be challenged.
Researchers have identified a section of the anthrax toxin Lethal Factor that could help produce a more effective vaccine. A 10-year study found that this protein elicits a highly effective immune response and works across a wide range of people, making it a promising target for future vaccines.
A recent measles outbreak in the US highlights the need for physicians to be familiar with the deadly disease, particularly in return travelers with fever and rash. The author emphasizes the importance of measles vaccination and vigilance in healthcare facilities to prevent further spread.
A comprehensive genomic analysis of Bordetella pertussis bacteria reveals the impact of vaccination on its spread and diversification. The study shows that vaccination has dramatically reduced rates of infection and loss of life from whooping cough, but strategies used to date have not completely eradicated strains of the bacteria.
Cornell scientists developed the first vaccines that can prevent metritis in dairy cows, reducing incidence by up to 83% and alleviating symptoms. The research could help curb antibiotic resistance and save the US billions annually.
A UNSW-led study found that 80% of 2012 Australian whooping cough cases were caused by pertactin-free strains, which may evade vaccine antibodies. The shift could reduce the vaccine's effectiveness in Australia.
A study found a significant reduction in HPV types 16 and 18 infections among young women in England after the introduction of the HPV vaccination program. The prevalence dropped from 1 in 5 to 1 in 15 among those aged 16-18, with the lowest rates among vaccinated individuals.
Researchers found that small financial incentives increased completion of hepatitis B vaccination among injecting drug users, with 45-49% completing the course compared to 9%. The study suggests offering financial incentives can be achieved in routine clinical practice and improve public health outcomes.
A new study by University of Pennsylvania researchers found that strain-specific Lyme disease immunity can last six to nine years. This finding has significant implications for vaccine design, as a single vaccine could potentially cover multiple strains of the disease-causing bacteria, substantially reducing the risk of infection.
Polymeric vaccine adjuvants in nanoparticles, matrices, or micelles can prompt strong adaptive immune responses. Researchers summarize the benefits and challenges of these polymer systems as adjuvants in vaccines.
A recent study in Human Vaccines & Immunotherapeutics found that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix are non-inferior to three doses, providing similar protection against cervical cancer. The two-dose schedule showed a clinically acceptable safety profile and induced strong antibody responses.
Researchers have developed a new technique using DNA vaccines to stimulate the immune system's response against HIV and Hepatitis C viruses. The technique, which has shown promising results in pre-clinical research, involves delivering a vaccination directly into the skin using a micro-needle device.
The Lancet journals publish a special collection on tuberculosis, highlighting emerging challenges like drug-resistant strains and poor treatment outcomes. New anti-tuberculosis drugs and host-directed therapies are being developed to improve treatment efficacy.
A study found that changing hospital orders increased pertussis immunization rates by 69% among new mothers, providing protection for themselves and their newborns. Implementing a standing order led to the largest increase in vaccinations, raising the rate from zero to 69%.
A recent study published on bmj.com found that the HPV vaccine significantly protects against cervical abnormalities in young women. The research estimated that three doses of the vaccine provided 46% protection against high-grade cervical abnormalities and 34% protection against other cervical abnormalities.